← Back to patent-cliff list
Irinotecan liposomal (CSPC)
Tier C — Watch / tradeIrinotecan liposomal (CSPC)
-
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TOP1
Indications (approved)：Pancreatic cancer
Regional status
US
Filed / under review
2023-12-18
EU
-
China
Approved
2023-09-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Irinotecan liposomal (CSPC)?
Approved indications include: Pancreatic cancer.
When does the Irinotecan liposomal (CSPC) patent expire?
No public expiry year is available for Irinotecan liposomal (CSPC) yet; this page updates once verified.
How do I get a quote for Irinotecan liposomal (CSPC) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01